Prescribing information



Start with Tasigna to help achieve long-term treatment success1,2

Image with the words 'the journey starts with Tasigna'


For the treatment of Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML).1,2


Tasigna is indicated for the treatment of:

  • Adult and paediatric patients with newly diagnosed Ph+ CML in the chronic phase
  • Adult patients with chronic phase and accelerated phase Ph+ CML with resistance or intolerance to prior therapy including imatinib▼. Efficacy data in patients with CML in blast crisis are not available
  • Paediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior therapy including imatinib1,2

What is Tasigna?

Tasigna is an oral, twice-daily potent inhibitor of the ABL tyrosine kinase activity of the BCR-ABL oncoprotein. In cell lines and in primary Ph+ leukaemia cells Tasigna selectively inhibits proliferation and induces apoptosis.1,2

  • In the ENESTnd study, patients treated with Tasigna experienced higher response rates than those treated with imatinib, and Tasigna demonstrated superior efficacy vs imatinib3–5
  • In a post hoc analysis more patients achieved early molecular response* with Tasigna than imatinib, a predictor of long-term benefits6,7
  • More than half of patients achieved MR4.5 by 5 years with Tasigna vs a third treated first line with imatinib1,2,8
  • >99% of all patients treated with Tasigna did not progress to AP/BC†8
  • In patients who achieved sustained MR4.5 on Tasigna and entered TFR, more than 50% remained in TFR1,2
  • Tasigna has a well-established tolerability and consistent safety profile1,2,9



* EMR is defined as BCR-ABL1 ≤10% at 3 months.9

In patients who remained on core treatment during the ENESTnd study.8

AP, accelerated phase; BC, blast crisis; CML, chronic myeloid leukaemia; CP, chronic phase; EMR, early molecular response; ENESTnd, Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients; MR4.5, molecular response 4.5; Ph+, Philadelphia chromosome positive; TFR, treatment-free remission.


  1. Tasigna® (nilotinib 200 mg and 50 mg) Summary of Product Characteristics. 2022.
  2. Tasigna® (nilotinib 150 mg) Summary of Product Characteristics. 2022.
  3. Saglio G, et al. N Engl J Med. 2010;362(24):2251–2259.
  4. Kantarjian HM, et al. Lancet Oncol. 2011;12(9):841–851.
  5. Larson RA, et al. Leukemia. 2012;26(1):2197–2203.
  6. Hughes TP, et al. Blood. 2014;123(9):1353–1360.
  7. Marin D, et al. J Clin Oncol. 2012;30(3):232–238.
  8. Hochhaus A, et al. Leukemia. 2016;30(5):1044–1054.
  9. Larson RA, et al. Blood. 2014;124(21):4541.
Rate this content: 
Average: 1 (1 vote)
UK | May 2022 | 205637

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at